Optimizing Caffeine Use and Risk of Bronchopulmonary Dysplasia in Preterm Infants

• Autores: Mitali Atul Pakvasa, Vivek Saroha, Ravi Mangal Patel
• Localización: Clinics in Perinatology, ISSN 0095-5108, Vol. 45, Nº. 2, 2018, págs. 273-291
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Caffeine reduces the risk of bronchopulmonary dysplasia (BPD). Optimizing caffeine use could increase therapeutic benefit. We performed a systematic-review and random-effects meta-analysis of studies comparing different timing of initiation and dose of caffeine on the risk of BPD. Earlier initiation, compared to later, was associated with a decreased risk of BPD (5 observational studies; n = 63,049, adjusted OR 0.69; 95% CI 0.64–0.75, GRADE: low quality). High-dose caffeine, compared to standard-dose, was associated with a decreased risk of BPD (3 randomized trials, n = 432, OR 0.65; 95% CI 0.43–0.97; GRADE: low quality). Higher quality evidence is needed to guide optimal caffeine use.